Mode
Text Size
Log in / Sign up

Medication-free major depressive disorder associated with age-dependent accelerated structural brain aging compared to healthy controls

Medication-free major depressive disorder associated with age-dependent accelerated structural brain…
Photo by Navy Medicine / Unsplash
Key Takeaway
Note that accelerated brain aging in MDD is age-dependent and linked to worse clinical outcomes, but is not uniform across all patients.

This observational cross-sectional MRI analysis evaluated age-dependent acceleration of structural brain aging in medication-free individuals with major depressive disorder (MDD) versus matched healthy controls. The study included 645 participants with MDD in a current depressive episode and 645 healthy controls recruited from 11 sites within the COORDINATE-MDD consortium. All MDD participants were medication-free to avoid confounding effects of pharmacotherapy on neuroimaging markers.

The primary outcome measured the brain age gap (BAG) and age-corrected BAG (cBAG). Results indicated that MDD was associated with a significantly elevated cBAG of +2.01 years compared to controls. When stratified by age, no differences were observed before mid-30s; however, gaps widened progressively thereafter. In individuals aged 55 and older, the cBAG difference reached +6.85 years in the MDD group.

Secondary outcomes assessed regional volumes across 145 regions and identified neuroanatomical phenotypes linked to differential antidepressant response, cognitive impairment, increased adverse life events, increased self-harm and suicide attempts, and a pro-atherogenic metabolic profile. Key contributing regions to the cBAG were identified, though specific effect sizes for regional contributions were not reported in the available data.

Safety data, including adverse events and tolerability, were not reported as this was an imaging study without active intervention. Limitations include reliance on summary-level data from previous studies, modest sample sizes, and a small percentage of MDD individuals older than 65 years. Clinicians should recognize that cBAG is not a uniform feature of MDD and seems to be more strongly expressed in a specifically clinically vulnerable disease phenotype.

Study Details

Sample sizen = 645
EvidenceLevel 5
PublishedApr 2026
View Original Abstract ↓
Background: Major depressive disorder (MDD) is associated with altered brain structure and evidence of accelerated brain aging. However, previous studies have been limited by clinical samples with mixed medication status and multiple mood states, modest sample sizes, small percentage of MDD individuals older than 65 years of age, and/or reliance on summary-level data. Methods: Harmonized T1-weighted MRI from MDD (n = 645), all medication-free and in a current depressive episode, and matched healthy controls (n = 645), segmented into 145 regional volumes, from 11 sites in COORDINATE-MDD consortium. Brain age gap (BAG) was estimated using gradient boosting regression with nested cross-validation. Group differences in BAG (and age-corrected BAG [cBAG]) were examined across age strata. Regional contributions were evaluated using Shapley Additive exPlanations. Results: MDD was associated with significantly elevated cBAG compared with healthy controls (mean difference + 2.01 years). Age-stratified analyses showed no differences before mid-30s, with progressively larger gaps thereafter, reaching +6.85 years in MDD aged 55 and older. cBAG differed across neuroanatomical phenotypes associated with differential antidepressant response, cognitive impairment, increased adverse life events, increased self-harm and suicide attempts, and a pro-atherogenic metabolic profile. Key contributing regions included lateral and medial prefrontal regions, middle temporal gyrus, putamen, supplementary motor cortex, central operculum, and cerebellum. Conclusions: Accelerated structural brain aging in MDD is age-dependent and is most pronounced in a neuroanatomical phenotype associated with worse key clinical outcomes. The findings support neuroprogression models of MDD while demonstrating that cBAG is not a uniform feature of MDD and seem to be more strongly expressed in a specifically clinically vulnerable disease phenotype.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.